两种远端保护装置对颈动脉支架术中易损斑块脑微栓塞影响的随机对照试验方案(CASH-ES)
本研究为前瞻性、单中心、随机、对照、盲法终点试验,计划纳入172例高危颈动脉狭窄患者,按1:1随机比较Spider FX™与Emboshield NAV6™两种远端栓塞保护装置在颈动脉支架术中的表现。主要结局为术后7天内弥散加权成像(DWI)上新发同侧缺血性病灶,次要结局包括病灶数量、大小、位置及术中经颅彩色多普勒(TCCD)监测的微栓子信号(MES)计数。
要点
- 比较Spider FX™与Emboshield NAV6™在CAS中的远端栓塞保护效果。
- 主要结局为术后7天DWI新发同侧缺血病灶。
- 样本量172例,按1:1随机,考虑20%脱落率。
核心结论
- 该试验将提供Emboshield NAV6™是否较Spider FX™具有更优远端栓塞保护效果的关键证据。
研究设计与样本
- 前瞻性、单中心、随机、对照、盲法终点试验,计划纳入172例高危颈动脉狭窄行CAS患者,按1:1随机分配至Spider FX™或Emboshield NAV6™组,考虑20%脱落率。
关键数值与推荐
- 主要结局为CAS术后7天内DWI上新发同侧缺血性病灶。
- 次要结局包括DWI新发缺血病灶的数量、大小、位置及术中TCCD监测的微栓子信号(MES)计数。
- 安全性评估包括术后7天内的操作并发症、心肌梗死和死亡。
局限性
- 研究仅针对中国人群,结果推广至其他种族需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carotid artery stenting (CAS) is a widely used procedure for patients with high-risk carotid stenosis, particularly in the Chinese population. However, there are no randomized trials examining the comparative efficacy and safety of different embolic protection devices (EPDs) used during CAS. This study aims to evaluate the safety and effectiveness of two newer-generation EPDs, Spider FX™ and Emboshield NAV6™, using a comprehensive approach that includes intraoperative monitoring, postoperative imaging, and clinical outcomes. Given the specific focus on a Chinese population, caution should be applied when generalizing findings to other ethnic groups. METHODS: This is a prospective, single-center, randomized, controlled, and blinded-endpoint trial designed to compare the performance of Spider FX™ and Emboshield NAV6™ in high-risk carotid stenosis patients undergoing CAS. A total of 172 patients will be enrolled, accounting for an estimated 20% dropout rate. The randomization will be performed in a 1:1 ratio between the two devices. The primary outcome is new ipsilateral ischemic lesions on diffusion-weighted imaging (DWI) within 7 days after CAS. Secondary outcomes include the number, size, and location of new cerebral ischemic lesions on DWI, and the count of microembolic signals (MES) detected by TCCD monitoring during the procedure. Safety assessments will include procedural complications, myocardial infarction, and mortality within 7 days. DISCUSSION: The results of this trial will provide crucial evidence on whether the Emboshield NAV6™ device offers superior distal embolic protection compared to the Spider FX™ in patients undergoing CAS. This could potentially guide clinicians in selecting the most effective EPD for high-risk carotid stenosis patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04904250 (URL: http://www. CLINICALTRIALS: gov ) Registered on May 27, 2021.
引用
- Yan L, Shu L, Xinyi S, et al. Two different distal protections on cerebral microembolization of vulnerable plaque during carotid artery stenting (CASH-ES): study protocol for a randomized controlled trial. Trials. 2026. PMID: 42001098. doi:10.1186/s13063-026-09687-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。